Antifungal resistance among Candida species

Pharmacotherapy

Volumn 21, Issue 8 SUPPL. 2, 2001, Pages

  Klepser, M E ^a  

^a BORGESS MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN B; ANTIFUNGAL AGENT; CASPOFUNGIN; ECHINOCANDIN B DERIVATIVE; FLUCONAZOLE; FLUCYTOSINE; ITRACONAZOLE; POLYENE; PYRROLE DERIVATIVE;

ANTIBIOTIC RESISTANCE; ANTIBIOTIC SENSITIVITY; ANTIFUNGAL ACTIVITY; CANDIDA; MINIMUM INHIBITORY CONCENTRATION; NONHUMAN; REVIEW;

CANDIDA;

EID: 0034910676     PISSN: 02770008     EISSN: None     Source Type: Journal    
DOI: 10.1592/phco.21.12.124s.34511     Document Type: Review

References (85)

1. An overview of nosocomial infections, including the role of the microbiology laboratory
2. Secular trends in nosocomial primary bloodstream infections in the United States, 1980-1989. National nosocomial infections surveillance system
3. Cross-sectional study of the susceptibility of Candida isolates to antifungal drugs and in vitro-in vivo correlation in HIV-infected patients
4. Isolation of fluconazole-resistant Candida albicans from human immunodeficiency virus-negative patients never treated with azoles
5. The changing face of candidemia: Emergence of non-Candida albicans species and antifungal resistance
6. Isolation and characterization of fluconazole- and amphotericin B-resistant Candida albicans from blood of two patients with leukemia
7. Bloodstream infections due to Candida species: SENTRY antimicrobial surveillance program in North America and Latin America, 1997-1998
8. Fluconazole susceptibilities of Candida species and distribution of species recovered from blood cultures over a 5-year period
9. Association of Torulopsis glabrata infections with fluconazole prophylaxis in neutropenic bone marrow transplant patients
10. Torulopsis glabrata infections in patients with cancer. Increasing incidence and relationship to colonization
11. Emergence of a new opportunistic pathogen, Candida lusitaniae
12. Nosocomial acquisition of Candida parapsilosis: An epidemiologic study
13. Increase in Candida krusei infection among patients with bone marrow transplantation and neutropenia treated prophylactically with fluconazole
14. Importance of Candida species other than C. albicans as pathogens in oncology patients
15. Secular trends in the epidemiology of nosocomial fungal infections in the United States, 1980-1990. National nosocomial infections surveillance system
16. National epidemiology of mycoses survey: A multicenter study of strain variation and antifungal susceptibility among isolates of Candida species
17. Development of interpretive breakpoints for antifungal susceptibility testing: Conceptual framework and analysis of in vitro-in vivo correlation data for fluconazole, itraconazole, and Candida infections. Subcommittee on antifungal susceptibility testing of the National Committee for Clinical Laboratory Standards
18. Antifungal susceptibility testing of isolates from a randomized, multicenter trial of fluconazole versus amphotericin B as treatment of nonneutropenic patients with candidemia
19. In vitro pharmacodynamic properties of MK-0991 determined by time-kill methods
20. Growth medium effect on the antifungal activity of LY 303366
21. Evaluation of endpoints for antifungal susceptibility determinations with LY303366
22. Amphotericin B as primary therapy for cryptococcosis in patients with AIDS: Reliability of relatively high doses administered over a relatively short period
23. Comparison of amphotericin B with fluconazole in the treatment of acute AIDS-associated cryptococcal meningitis
24. Treatment of cryptococcal meningitis associated with the acquired immunodeficiency syndrome
25. In vitro activity of a new semisynthetic echinocandin, LY-303366, against systemic isolates of Candida species, Cryptococcus neoformans, Blastomyces dermatitidis, and Aspergillus species
26. In vitro preclinical evaluation studies with the echinocandin antifungal MK-0991 (L-743,872)
27. The epidemiology of hematogenous candidiasis caused by different Candida species
28. National surveillance of nosocomial blood stream infection due to Candida albicans: Frequency of occurrence and antifungal susceptibility in the SCOPE program
29. Candidemia in cancer patients: A prospective, multicenter surveillance study by the invasive fungal infection group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC)
30. Infection due to fluconazole-resistant Candida in patients with AIDS: Prevalence and microbiology
31. Risk factors for fluconazole-resistant candidiasis in human immunodeficiency virus-infected patients
32. Fluconazole- and itraconazole-resistant Candida albicans strains from AIDS patients: Multilocus enzyme electrophoresis analysis and antifungal susceptibilities
33. Emergence of azole drug resistance in Candida species from HIV-infected patients receiving prolonged fluconazole therapy for oral candidosis
34. Fluconazole-resistant Candida albicans after long-term suppressive therapy
35. Emergence of fluconazole-resistant strains of Candida albicans in patients with recurrent oropharyngeal candidosis and human immunodeficiency virus infection
36. Oral Candida albicans isolates with reduced susceptibility to fluconazole in Swedish HIV-infected patients
37. Clinically significant mucosal candidiasis resistant to fluconazole treatment in patients with AIDS
38. Resistance of Candida albicans to fluconazole during treatment of oropharyngeal candidiasis in a patient with AIDS: Documentation by in vitro susceptibility testing and DNA subtype analysis
39. Variations in fluconazole susceptibility and electrophoretic karyotype among oral isolates of Candida albicans from patients with AIDS and oral candidiasis
40. Fluconazole-resistant recurrent oral candidiasis in human immunodeficiency virus-positive patients: Persistence of Candida albicans strains with the same genotype
41. Resistance to antifungal agents in the critical care setting: Problems and perspectives
42. Role of cell defense against oxidative damage in the resistance of Candida albicans to the killing effect of amphotericin B
43. Incidence of polyene-resistant yeasts recovered from clinical specimens
44. Sterol content and polyene antibiotic resistance in isolates of Candida krusei, Candida parakrusei, and Candida tropicalis
45. High-frequency, in vitro reversible switching of Candida lusitaniae clinical isolates from amphotericin B susceptibility to resistance
46. Molecular mechanisms of drug resistance in fungi
47. Resistance to amphotericin B associated with defective sterol delta 8→7 isomerase in a Cryptococcus neoformans strain from an AIDS patient
48. Fluorescence studies on the molecular action of amphotericin B on susceptible and resistant fungal cells
49. Polyene resistance in ergosterol producing strains of Candida albicans
50. Mode of action and resistance to azole antifungals associated with the formation of 14 alpha-methylergosta-8,24(28)-dien-3 beta,6 alpha-diol
51. The presence of an R467K amino acid substitution and loss of allelic variation correlate with an azole-resistant lanosterol 14alpha demethylase in Candida albicans
52. The mutation T315A in Candida albicans sterol 14alpha-demethylase causes reduced enzyme activity and fluconazole resistance through reduced affinity
53. Molecular analysis of cyp51 from fluconazole-resistant Candida albicans strains
54. Clinical, cellular, and molecular factors that contribute to antifungal drug resistance
55. Mechanisms of resistance to azole antifungal agents in Candida albicans isolates from AIDS patients involve specific multidrug transporters
56. Increased mRNA levels of ERG16, CDR, and MDR1 correlate with increases in azole resistance in Candida albicans isolates from a patient infected with human immunodeficiency virus
57. Multiple efflux mechanisms are involved in Candida albicans fluconazole resistance
58. Multiple molecular mechanisms contribute to a stepwise development of fluconazole resistance in clinical Candida albicans strains
59. Upregulation of ERG genes in Candida species by azoles and other sterol biosynthesis inhibitors
60. Overexpression of Erg11p by the regulatable GAL1 promoter confers fluconazole resistance in Saccharomyces cerevisiae
61. Characterization of an azole-resistant Candida glabrata isolate
62. Rapid detection and identification of Candida albicans and Torulopsis (Candida) glabrata in clinical specimens by species-specific nested PCR amplification of a cytochrome P-450 lanosterol-alpha-demethylase (L1A1) gene fragment
63. Mechanism of fluconazole resistance in Candida krusei
64. Cloning of Candida albicans genes conferring resistance to azole antifungal agents: Characterization of CDR2, a new multidrug ABC transporter gene
65. Distinct patterns of gene expression associated with development of fluconazole resistance in serial Candida albicans isolates from human immunodeficiency virus-infected patients with oropharyngeal candidiasis
66. Rapid, transient fluconazole resistance in Candida albicans is associated with increased mRNA levels of CDR
67. A comparison of the sterol content of multiple isolates of the Candida albicans Darlington strain with other clinically azole-sensitive and -resistant strains
68. Deletion of the Candida glabrata ERG3 and ERG11 genes: Effect on cell viability, cell growth, sterol composition, and antifungal susceptibility
69. Modulation of fluconazole sensitivity by the interaction of mitochondria and erg3p in Saccharomyces cerevisiae
70. Mechanisms and clinical impact of antifungal drug resistance
71. Evidence for a common transport system for cytosine, adenine and hypoxanthine in Saccharomyces cerevisiae and Candida albicans
72. Anti-Candida drugs - The biochemical basis for their activity
73. Mode of action of 5-fluorocytosine and mechanisms of resistance
74. Mode of action of 5-fluorocytosine
75. Mechanisms of action of 5-fluorocytosine
76. The genetic basis of resistance to 5-fluorocytosine in Candida species and Cryptococcus neoformans
77. Characterization of echinocandin-resistant mutants of Candida albicans: Genetic, biochemical, and virulence studies
78. Identification of the FKS1 gene of Candida albicans as the essential target of 1,3-beta-D-glucan synthase inhibitors
79. Differential expression and function of two homologous subunits of yeast 1,3-beta-D-glucan synthase
80. The Saccharomyces cerevisiae FKS1 (ETG1) gene encodes an integral membrane protein which is a subunit of 1,3-beta-D-glucan synthase
81. Declining rates of oropharyngeal candidiasis and carriage of Candida albicans associated with trends toward reduced rates of carriage of fluconazole-resistant C. albicans in human immunodeficiency virus-infected patients
82. Experimental induction of fluconazole resistance in Candida tropicalis ATCC 750
83. Antifungal pharmacodynamic characteristics of fluconazole and amphotericin B tested against Candida albicans
84. In vitro pharmacodynamic characteristics of nystatin including time-kill and postantifungal effect